Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06232577 · ClinicalTrials.gov registry record · Phase 2

5x-Multiplier vs 3-Tier Model for Discharge Opioid Prescriptions After Intra-abdominal Cancer Surgery: A Randomized Clinical Trial

A Phase 2 study of Intra-abdominal Cancer, sponsored by M.D. Anderson Cancer Center.

Active
Registry status
Phase 2
Development phase
170
Enrollment target
1
Study location

NCT06232577 is a Phase 2 study of Intra-abdominal Cancer that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 170 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06232577, a Phase 2 study of Intra-abdominal Cancer, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
170 participants
Enrollment target
1
Study location

Study Summary

To compare 2 different models for prescribing opioid pain medication to provide better pain control to participants with an abdominal cancer who are having surgery.

Conditions Studied

Interventions

  • DRUG Oxycodone
  • DRUG Tramadol
  • DRUG Hydrocodone

Study Locations (1)

Texas

  • MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 170 participants
Start Date 2024-03-27
Est. Completion 2026-12-31
Phase Phase 2

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

What the Registry Record Tells You About NCT06232577

The ClinicalTrials.gov registry entry for NCT06232577 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 170 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Intra-abdominal Cancer appearing as the primary indexed condition, and to 3 interventions - of which Oxycodone is the first listed.

NCT06232577 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT06232577 about?

NCT06232577 is a clinical study titled "5x-Multiplier vs 3-Tier Model for Discharge Opioid Prescriptions After Intra-abdominal Cancer Surgery: A Randomized Clinical Trial". To compare 2 different models for prescribing opioid pain medication to provide better pain control to participants with an abdominal cancer who are having surgery.

What is the current status of trial NCT06232577?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 170 participants. The study started on 2024-03-27. Estimated completion is 2026-12-31.

What conditions does trial NCT06232577 study?

This clinical trial studies the following conditions: Intra-abdominal Cancer.

What interventions are being tested in trial NCT06232577?

The interventions under investigation include: Oxycodone (DRUG), Tramadol (DRUG), Hydrocodone (DRUG).

Who is sponsoring clinical trial NCT06232577?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06232577 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Intra-abdominal Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.